Skystar Bio-Pharma (SKBI) Reports Q2 EPS of $0.37
Tweet
Share
E-mailGet Alerts SKBI Hot Sheet
Join SI Premium – FREE
Skystar Bio-Pharma (NASDAQ: SKBI) reported Q2 EPS of $0.37, versus $0.49 reported last year. Revenue for the quarter came in at $14.2 million, versus $11.3 million reported last year.
For earnings history and earnings-related data on Skystar Bio-Pharma (SKBI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
- Faraday Future stockholders approve $25M private placement proposal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
